GlassScriptPhysician profile
Andrew R Harbison
NPI 1861400772
$28,951.08
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $676 · 2021: $11K · 2022: $18K.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $28,298.38 | 2019-2022 | |
| Amgen INC. | $191.30 | 2019 | |
| Merck Sharp & Dohme LLC | $130.21 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $54.39 | 2019 | |
| Sanofi Pasteur INC. | $40.76 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $38.07 | 2019 | |
| Janssen Pharmaceuticals, INC | $37.56 | 2019 | |
| Novo Nordisk INC | $34.52 | 2019 | |
| Assertio Therapeutics, INC. | $26.64 | 2019 | |
| Abbvie INC. | $21.32 | 2019 | |
| Amneal Pharmaceuticals LLC | $19.78 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $19.50 | 2019 | |
| Lilly USA, LLC | $15.75 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.54 | 2019 | |
| Pfizer INC. | $11.36 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Harbison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.